KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Revenue: 2009-2025

Historic Revenue for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $3.8 billion.

  • Regeneron Pharmaceuticals' Revenue rose 0.90% to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 billion, marking a year-over-year increase of 2.89%. This contributed to the annual value of $14.2 billion for FY2024, which is 8.27% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Revenue stood at $3.8 billion for Q3 2025, which was up 2.14% from $3.7 billion recorded in Q2 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Revenue registered a high of $5.1 billion during Q2 2021, and its lowest value of $50.0 million during Q1 2022.
  • In the last 3 years, Regeneron Pharmaceuticals' Revenue had a median value of $3.4 billion in 2023 and averaged $3.4 billion.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 98.02% in 2022, then skyrocketed by 6,224.20% in 2023.
  • Regeneron Pharmaceuticals' Revenue (Quarterly) stood at $5.0 billion in 2021, then crashed by 97.98% to $100.0 million in 2022, then skyrocketed by 3,334.30% to $3.4 billion in 2023, then climbed by 10.33% to $3.8 billion in 2024, then grew by 0.90% to $3.8 billion in 2025.
  • Its Revenue was $3.8 billion in Q3 2025, compared to $3.7 billion in Q2 2025 and $3.0 billion in Q1 2025.